More on ERNA

- Summary
- Chart
- Profile
- Historical

Data

- Earnings
- Ratings (10.0 Score)

Upcoming Events

- Earnings (11/11/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Eterna Therapeutics (NQ:ERNA)
Delayed: 2.11 +0.13 (6.57%)
Prev. Close $1.98  
Open$2.03 
52 Wk High$ 
52 Wk Low$ 
Day High$2.11 
Day Low$2.00 
P/E N/A  
EPS$ 
Volume7,266 

Friends, Peers and Foes (?): LLY, NTHI, VIVS RFL (more...)

Oct 22, 2026 08:53 AM Ernexa Therapeutics Highlights ERNA-101’s Path Toward the Clinic and Differentiated Cell Therapy Platform in New “What This Means” Segment
Oct 15, 2026 05:25 PM Form 8-K Ernexa Therapeutics Inc. For: Oct 15
Oct 12, 2026 04:05 PM Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series
Oct 6, 2026 08:58 AM Ernexa presents ERNA-101 ovarian cancer data at MD Anderson event
Oct 6, 2026 08:55 AM Ernexa Therapeutics’ ERNA-101 Selected for Flash Talk Presentation at Nature Conferences’ Next-Generation Cancer Therapeutics Meeting Co-Hosted by MD Anderson Cancer Center
Oct 1, 2026 09:20 AM Ernexa appoints oncology veteran Spiegel to board ahead of clinic
Oct 1, 2026 09:20 AM Ernexa Therapeutics CEO Corner Highlights Appointment of Dr. Robert J. Spiegel as Company Sharpens Oncology Focus and Advances ERNA-101 Toward the Clinic
Sep 30, 2026 08:33 AM Ernexa reports positive safety data for ERNA-101 cell therapy
Sep 30, 2026 08:32 AM Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 IND
Sep 29, 2026 09:15 AM Ernexa Therapeutics Selected for Emerging Track at 2026 Cell & Gene Meeting on the Mesa, Highlighting ERNA-101 and Focused Oncology Strategy
View All Articles

Entities mentioned with ERNA

View All Entities